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Obesity and saturated fatty acid (SFA) treatment are both associated with skeletal muscle insulin resis-
tance (IR) and increased macrophage infiltration. However, the relative effects of SFA and unsaturated
fatty acid (UFA)-activated macrophages on muscle are unknown. Here, macrophages were treated with
palmitic acid, palmitoleic acid or both and the effects of the conditioned medium (CM) on C2C12 myo-
tubes investigated. CM from palmitic acid-treated J774s (palm-mac-CM) impaired insulin signalling
and insulin-stimulated glycogen synthesis, reduced Inhibitor jBa and increased phosphorylation of
p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase in myotubes. p38 MAPK inhi-
bition or siRNA partially ameliorated these defects, as did addition of tumour necrosis factor-a blocking
antibody to the CM. Macrophages incubated with both FAs generated CM that did not induce IR, while
palmitoleic acid-mac-CM alone was insulin sensitising. Thus UFAs may improve muscle insulin sensitiv-
ity and counteract SFA-mediated IR through an effect on macrophage activation.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CCBY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Insulin resistance (IR) in skeletal muscle develops in advance of
type 2 diabetes (T2D) in humans and typically occurs alongside
obesity and elevated plasma lipid and fatty acid (FA) levels. It is
well-established that accumulation of lipid derivatives in skeletal
muscle results in IR (Turner et al., 2014) and that saturated (SFAs)
impair insulin-stimulated glucose disposal through inhibition of
the phosphoinositol 3-kinase (PI3K)/protein kinase B (Akt) signal-
ling pathway (Cazzolli et al., 2001; Dimopoulos et al., 2006;Griffin et al., 1999; Hirabara et al., 2010; Hommelberg et al.,
2011; Kadotani et al., 2009; Storlien et al., 1991), while some
unsaturated fatty acids (UFAs) have been shown to have insulin
sensitising effects (Kadotani et al., 2009; Tardif et al., 2011) and
to be capable of negating the deleterious effects of SFAs (Coll
et al., 2008; Dimopoulos et al., 2006; Gao et al., 2009; Storlien
et al., 1991). Obesity represents a subclinical inflammatory state,
evidenced by an association with markers of systemic inflamma-
tion (Festa et al., 2002) and increased infiltration of innate immune
cells, including macrophages, into obese adipose tissue (Cancello
et al., 2005; Elgazar-Carmon et al., 2008; Weisberg et al., 2003).
The normal resident macrophage population in lean adipose tissue
is modified in obesity. Resident adipose macrophages in lean indi-
viduals are predominantly activated towards an M2-like pheno-
type and release anti-inflammatory cytokines, such as interleukin
(IL)-10, which are insulin sensitising (Lumeng et al., 2007a). How-
ever, in obesity macrophage phenotype switches towards a more
pro-inflammatory M1-like subtype and/or they release chemo-
kines that recruit additional macrophages (Lumeng et al., 2007a;
Lumeng et al., 2007b; Prieur et al., 2011).
It is as yet unclear whether FAs or other lipid derivatives are
responsible for direct activation of macrophages or if macrophages
are activated by signals from other tissues or cells, given the exten-
sive cross-talk that occurs between adipocytes and infiltrating
inflammatory cells (Lumeng et al., 2007a,b; Prieur et al., 2011).
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receptors (TLR) on macrophages (Hwang, 2001; Lee et al., 2001;
Nguyen et al., 2007), leading to activation of inflammatory path-
ways such as the classical nuclear factor-jB (NF-jB) and c-jun
n-terminal kinase (JNK) pathways and elevated production of
pro-inflammatory cytokines (Haversen et al., 2009; Hwang, 2001;
Samokhvalov et al., 2008; Shi et al., 2006), while this effect can
be blocked by UFAs (Haversen et al., 2009; Lee et al., 2004). A
widely demonstrated mechanism whereby cytokines and SFAs
may induce IR is via activation of stress kinases and inhibitory ser-
ine phosphorylation of insulin receptor substrate-1 (IRS-1) (McCall
et al., 2010; Solinas et al., 2006), a key adaptor protein activating
phosphoinositol 3-kinase (PI3K) signalling and thus insulin-stimu-
lated glucose disposal in muscle. These kinases include the mito-
gen-activated protein kinases (MAPKs) c-jun n-terminal kinase
(JNK), p38 MAPK and Inhibitor jB kinase, upstream of NFjB and
indeed the deletion of JNK-1 (Hirosumi et al., 2002) and IjB kinase
(IKK) (Yuan et al., 2001) prevented high-fat diet (HFD) – induced IR
in mice.
Whereas some studies have demonstrated that macrophages
accumulate in tissues other than adipose during obesity, including
skeletal muscle ((Fink et al., 2013; Hevener et al., 2007; Nguyen
et al., 2007); NAT, CWJ and MEC, unpublished data) little attention
has been paid to the potential impact of this upon muscle insulin
sensitivity. However, a recent study suggested that macrophages
in muscle from obese individuals may also contribute to the
increase in pro-inflammatory cytokine release and thus muscle IR
(Varma et al., 2009). Furthermore, after incubation with the SFA
palmitic acid, pro-inflammatory pathways are activated in macro-
phages, leading to IR in adipocytes through a paracrine loop involv-
ing tumour necrosis factor (TNF)a (Suganami et al., 2005), which
has been repeatedly shown to induce IR in muscle cells in vitro
and in vivo (de Alvaro et al., 2004; Hotamisligil et al., 1994; Liang
et al., 2008; Plomgaard et al., 2005; Uysal et al., 1997). The effects
of TNFa may be mediated through p38 MAPK, as inhibition or
silencing of this kinase in vitro ameliorated TNFa-induced skeletal
muscle IR (de Alvaro et al., 2004).
Recently, palmitic acid-treated macrophages were shown to
generate conditioned medium (CM) that reduced glucose uptake
and PI3K signalling and increased inflammatory signalling in
GLUT4-overexpressing L6 myoblasts (Samokhvalov et al., 2008),
an effect that was mediated through induction of protein kinase
C (PKC) h and e isoforms (Kewalramani et al., 2011). In addition,
CM from FA-treated macrophages caused IR in L6 myotubes that
was TLR2/4-dependent (Nguyen et al., 2007). Conversely, CM from
palmitic acid-treated myoblasts was capable of causing a pro-
inflammatory switch in macrophage phenotype (Pillon et al.,
2012). However, it is unclear whether UFAs might be able to alle-
viate these effects. Here, we aimed to further interrogate the mech-
anisms involved in the impairment of insulin sensitivity in
differentiated skeletal muscle cells generated by CM derived from
SFA-treated macrophages and to establish whether UFA treatment
would alleviate these effects.2. Materials and methods
2.1. Materials
General reagents were from Sigma–Aldrich (Gillingham, Dorset,
UK), cell culture media from Gibco (Life Technologies, Paisley, UK)
and recombinant TNFa from eBiosciences (Hatfield, UK). pY612-
IRS1 antibody was from Biosource International (Camarillo, CA,
USA), total IRS-1 and total glycogen synthase kinase (GSK) 3b anti-
bodies from Millipore (Billerica, MA, USA), b-actin antibody fromSigma and all others from Cell Signaling Technology (Beverley,
MA, USA).
2.2. Cell culture
C2C12 myoblasts and J774 macrophages were cultured in
DMEM containing 4.5 mM glucose, 10% foetal bovine serum (FBS)
and 1% antibiotic anti-fungal (ABAF) mixture. Before study, differ-
entiation of myoblasts into myotubes was achieved by switching to
DMEM containing 2% horse serum for 5 days. Macrophages were
treated with 200 ng/ml phorbol myristate acetate (PMA) for 3 days
before use (Karten et al., 1999). Macrophage treatment medium
was generated by coupling DMEM containing 10% FBS, 1% ABAF
and 2% bovine serum albumin (BSA) with 0.75 mM palmitic acid
(SFA), 0.75 mM palmitoleic acid (UFA, chosen because of its identi-
cal acyl chain length), a combination of both, or 10 ng/ml of lipo-
polysaccharide (LPS) as positive control. This was added to J774
cells for 8 h, before being aspirated and the cells washed in PBS
x3. Absence of carry-over of FAs into the CM was confirmed by
measurement using a kit (Wako Chemicals, Neuss, Germany).
Fresh DMEM was then added for 16 h and the CM generated trans-
ferred to C2C12 myotubes for a further 16 h. Myotubes were then
serum-starved for 2 h and selected wells stimulated with 100nM
insulin (Novo Nordisk, Crawley, UK) prior to measurement of
glycogen synthesis or lysis and western blotting.
2.3. Use of inhibitors
Where pharmacological inhibitors were used, myotubes were
pre-treated for 1 h with 1 lM SB203580 and 0.1 lM BIRB796,
1 lM JNK V inhibitor, or vehicle (DMSO), before being treated with
CM containing the same substances for 16 h. Where siRNA was
employed, C2C12s were transfected with 50 nM nonsense or
p38aMAPK-targeting siRNA pool using Dharmafect 3 (Dharmacon,
Fisher Scientific, Loughborough, UK) on day 2 of differentiation and
then left for 72 h before treatment with CM. Where TNFa blockade
was undertaken, half of the CM for each treatment group contained
10 lg/ml of blocking antibody (eBioscience, Hatfield, UK), added
before and during myotube incubation with control, palmitic acid
or LPS-treated macrophage-CM for 16 h.
2.4. SDS–PAGE and immunoblotting
Myotubes were lysed in radioimmunoprecipitation assay (RIPA)
buffer, homogenised using an Ultra-Turrax (IKA; Staufen, Ger-
many) and denatured in Laemmli buffer for 10 min at 65 C. Pro-
teins were resolved by SDS–PAGE, electro-transferred and
immunoblotted as previously described (Patel et al., 2012). Specific
bands were detected using chemoluminescence (Western Light-
ning Plus, Perkin Elmer) on Fuji Super RX film (Bedford, UK),
scanned and quantified using Quantity One software (BioRad Lab-
oratories, Hemel Hempstead, UK). Loading controls of correspond-
ing total protein immunoreactivity or b-actin were utilised. All
treatment groups were represented on each blot on which bands
were quantified.
2.5. Real-time PCR analysis
Macrophages were collected in Trizol (Invitrogen, Paisley, UK)
and homogenised using the Ultra-Turrax. Total RNA was extracted
as per the manufacturer’s instructions and resuspended in nucle-
ase-free water. RNA concentration was determined using a Nano-
drop 1000 (Wilmington, DE) and integrity confirmed by
visualisation of rRNA bands after agarose gel electrophoresis.
RNA preparations were DNAse-digested and cDNA was generated
using an Omniscript kit (Qiagen, Manchester, UK). Real-time PCR
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(Roche Diagnostics, Burgess Hill, UK) on an Opticon 2 detector
(Bio-Rad Laboratories, Hemel Hempstead, UK). Reaction mixtures
contained 20 ng of cDNA, 1.5 M each primer, 2.5 mMMgCl2, and
were subjected to a 10 min hot start, followed by 37 cycles of
15 s at 95 C, 60 s at 55–62 C and 30 s at 72 C, with a final
5 min extension. Primer pairs (Invitrogen) were designed using
the Primer3 program (http://bioinfo.ut.ee/primer3-0.4.0/).
Sequences were TNFa: GTAGCCCACGTCGTAGCAA and GTGGGTG
AGGAGCACGTAGT, MCP-1: ACCAGCCAACTCTCACTGAA and ACAG
CTTCTTTGGGACACTT, nitric oxide synthase-2 (NOS2): TGACCTGA
AAGAGAAAAGGA and TCCAGGGATTCTGGAACATT, 36B4: ACAGC
TTCTTTGGGACACTT and ATCTGCTGCATCTGCTTG. The relative
abundance of duplicate cDNA aliquots was quantified using a stan-
dard curve plotted from amplification of a 10-fold dilution series of
DNA generated by conventional PCR from the same primer pairs
and gel purified. Results are quoted after normalisation to expres-
sion of 36B4, which was unchanged by the treatments. Generation
of a single appropriate PCR product was confirmed by melting
curve analysis and periodic agarose gel electrophoresis.2.6. Glycogen synthesis
Incorporation of glucose into glycogen by myotubes was mea-
sured as previously described (Cazzolli et al., 2001). C2C12 myotu-
bes were serum starved and then 2 lCi D-[U-14C]-glucose (NEN/
Perkin–Elmer; Waltham, MA, USA) was added per well ±100 lM
insulin for one hour. The reaction was terminated by washing 3
with ice cold PBS. Myotubes were lysed in RIPA buffer at 100 C
for 10 min. Protein content was measured using a bicinchoninic
acid assay (Pierce Biotechnology, Rockford, IL). Glycogen was pre-
cipitated in ethanol at 4 C overnight, then at 20 C for 1 h, before
centrifugation at 13,000g for 20 min. The pellet was dissolved in
water at 60 C, mixed with scintillant (Ultima Gold, Perkin–Elmer)
and counted using a LS6500 beta counter (Beckman Coulter, UK).
Results were calculated as pmol/min/mg of protein.2.7. ELISA for secreted peptides
CM was centrifuged at 13,000g for 10 min and the cell-free
medium aliquoted into collection tubes and stored at 80 C until
analysis. Quantikine colormetrix sandwich ELISAs (R&D Systems,
Minneapolis, MN, USA) were used to measure levels of TNFa,
IL1b, Chemokine (C-X-C motif) ligand 2 (CXCL2) and monocyte
chemoattractant protein (MCP)1. Samples were diluted where nec-
essary and the procedure carried out according to the manufac-
turer’s instructions. Absorbance was measured on a microplate
reader (Tecan, Reading, UK) at 450 nm and corrected by the absor-
bance at 540 nm.2.8. Arginase assay
J774 cells were treated with FA-containing medium for 16 h
overnight and then washed in PBS before being collected and lysed
in 150 ll buffer containing 0.1% Triton X-100/10 mM MnCl2/
25 mM Tris–HCl. Lysates were frozen overnight, defrosted and
arginase activity was measured as previously described (Corraliza
et al., 1994). 50 ll of lysate was incubated with 50 ll of 0.5 M
L-arginine (pH 9.7) for 120 min at 37 C. The reaction was stopped
by the addition of H2SO4/H3PO4/H2O (1:3:7) and then 25 ll 9%
a-Isonitrosopropiophenone in ethanol was added and the mixture
heated to 100 C for 45 min. Samples were then cooled on ice for
30 min before measurement of absorbance at 550 nm.2.9. Griess assay
Inducible nitric oxide synthase (iNOS) activity was assessed by
measurement of NO release into the medium. J774 cells were acti-
vated with PMA for 3 days and then incubated with phenol red-
free DMEM containing BSA-coupled palmitic acid, palmitoleic acid,
a combination of both, LPS or vehicle for 16 h. Samples of medium
were collected at the end of this experiment, aliquoted into collec-
tion tubes and stored at 20 C before analysis. The Griess assay
was performed as a 96 well microplate assay (Molecular Probes,
Life Technologies, UK) according to the manufacturer’s instructions
and absorbance was read on the plate reader at 548 nm.
2.10. Statistics
Statistical analysis of data was performed using GraphPad Prism
6 (GraphPad Software, San Diego, CA, USA). Student’s t-test, one-
way and two-way ANOVAs were utilised, accompanied as appro-
priate by post hoc testing using Fisher’s least significant difference
test. Statistical significance was accepted at p < 0.05.3. Results
3.1. Insulin-stimulated glycogen synthesis in C2C12 myotubes is
impaired in the presence of palmitic acid-treated macrophage-
conditioned medium
To determine whether CM from macrophages affected glucose
disposal or insulin signalling in myotubes, the incorporation of
radiolabelled glucose into glycogen and the phosphorylation of
insulin signaling intermediates were assessed ± insulin. 100nM
insulin caused a 142% increase in glycogen synthesis (p = 0.0002),
while both positive control LPS-treated macrophage CM (LPS-
mac-CM) and palmitic acid-treated macrophage CM (palm-mac-
CM) prevented the effect of insulin, with palm-mac-CM causing a
54% reduction (p = 0.0005) and LPS-mac-CM a 42% reduction
(p = 0.0036) versus control CM (Fig. 1A). Insulin stimulation caused
substantial increases in phosphorylation of IRS1 (pY612), Akt
(pS473), GSK3b (pS9) and TBC1D4/Akt substrate of 160 kDa
(AS160; pT642). Both Palm-mac-CM and LPS-mac-CM caused
impaired insulin-stimulated phosphorylation of all of these inter-
mediates. LPS-mac-CM caused reductions in phosphorylation of
IRS1 (by 61%, p = 0.0006), Akt (by 29%, p = 0.0026), GSK3b (by
30%, p = 0.0039) and AS160 (by 52%, p = 0.0043) compared to con-
trol-mac-CM (Fig. 1B–E), while palm-mac-CM caused reductions in
IRS1 (by 44%, p = 0.048), Akt (by 47%, p < 0.0001), GSK3b (by 35%,
p = 0.0009) and AS160 (by 45%, p = 0.012) phosphorylation
(Fig. 1B–E). There were no effects on total protein levels of these
signalling intermediates or on their degree of phosphorylation in
the absence of insulin. Thus both LPS- and palm-mac-CM treat-
ment caused impairment in insulin-stimulated glycogen synthesis,
associated with impaired insulin signalling from the level of IRS1.
3.2. Treatment of macrophages with palmitoleic acid generates
conditioned medium that insulin sensitises myotubes
After macrophages were simultaneously incubated with both
palmitoleic acid and palmitic acid, the generated CM (comb-mac-
CM) did not cause a significant impairment in insulin-stimulated
glycogen synthesis in myotubes, as the palm-mac-CM-induced def-
icit was reduced by 66% (76% higher than palm-mac-CM,
p = 0.0139; Fig. 1A). Furthermore, CM generated frommacrophages
treated with palmitoleic acid alone (palmitoleic-mac-CM)
increased both basal and insulin-stimulated glycogen synthesis
versus the equivalent controls (by 92% and 40%, p = 0.008 and
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Fig. 1. Palmitic acid-treated macrophage-conditioned medium impairs glycogen synthesis and insulin signalling in C2C12 myotubes, while these defects are rescued by
palmitoleic acid. C2C12 myotubes were incubated with conditioned medium derived frommacrophages treated with LPS, palmitic acid, palmitoleic acid, a combination of the
two or vehicle (control group) for 16 h, before being serum starved and (A) incubated with D-[U-14C]-glucose tracer ± 100nM insulin to measure glycogen synthesis, or
collected in RIPA buffer and SDS–PAGE and immunoblotting conducted to assess phosphorylation and total protein levels of (B) IRS1 (pY612), (C) Akt (pS473), (D) GSK3b (pS9)
and (E) AS160 (pT642). Representative blots and summary data (mean ± SEM of 3–6 individual experiments) are shown. All treatment groups were represented on each blot
on which bands were quantified, but basal and insulin-stimulated samples are shown separately here for clarity. Total protein levels of all intermediates and b-actin were
unchanged by any treatment. Selected post hoc significance is shown to simplify interpretation: ##p < 0.01, ###p > 0.001 and ####p < 0.0001 vs. basal control; *p < 0.05,
**p < 0.01, ***p < 0.001 and ****p < 0.0001 vs. control, insulin treated cells; £p< 0.05, ££p < 0.01 and ££££p < 0.0001 versus palmitate treated, insulin treated cells. C – Control
(+ insulin treatment); P – Palmitic acid (+ insulin treatment); L – LPS (+ insulin treatment); PO – Palmitic and palmitoleic acid (+ insulin treatment); O – Palmitoleic acid
(+ insulin treatment).
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stimulated phosphorylation of PI3K signalling pathway intermedi-
ates were largely abrogated when palmitoleate was added to the
palmitate-BSA used to treat macrophages. Myotubes incubated
with comb-mac-CM showed a 90% increase in pY612-IRS1compared to palm-mac-CM (p = 0.0017), thus restoring phosphory-
lation to the level of insulin-treated control CM-incubated
myotubes (Fig. 1B). Phosphorylation of Akt, GSK3b and AS160 was
also variably restored in myotubes (p = 0.0026–0.060; Fig. 1C–E).
In addition, consistent with the elevated glycogen synthesis,
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Fig. 1B), pS9-GSK3b (by 39%, p = 0.0007; Fig. 1D) and pT642 (by
64%, p = 0.0006; Fig. 1E) versus insulin-stimulated control-mac-
CM-treated myotubes, while this effect was not detected with
respect to pS473-Akt. Total protein levels of each intermediate
were again unchanged. Thus, palmitoleic acid treatment of macro-
phages results in CM that insulin sensitises myotubes and can
rescue the defect in glycogen synthesis caused by palm-mac-
CM treatment of myotubes.
3.3. Palmitic acid and palmitoleic acid-treated macrophage-
conditioned media have contrasting effects on inflammatory signalling
in C2C12 myotubes
To determine whether palm-mac-CM might activate inflamma-
tory/stress signalling pathways in myotubes, immunoblotting was
performed initially for phosphorylated and total MAPKs and Inhib-
itor jBa (IjBa), which causes cytoplasmic retention of NFjB.
Although most of these pathways were activated by palm-mac-
CM and LPS-mac-CM, interestingly these effects were only appar-
ent under insulin-stimulated conditions. Both LPS- and palm-
mac-CM caused increases in pY182-p38 MAPK (p = 0.0003 and
p = 0.0024; Fig. 2A), accompanied by increases in pY185/pT183-
p46 JNK (p = 0.0034 and p = 0.010) and pY185/T183-p54 JNK
(p = 0.0001 and p = 0.0010; Fig. 2B&C), indicative of greater activa-
tion of each kinase. A similar trend was observed for ERK phos-
phorylation after palm-mac-CM but not LPS-mac-CM treatment
(Fig. 2D). Total protein levels of each were unaltered. Insulin treat-
ment increased IjBa (by 512%, p = 0.0010) but palm-mac-CM
especially reversed this effect (58% decrease, p = 0.0041; Fig. 2E),
implying activation of the NFjB pathway. Thus multiple pro-
inflammatory pathways are activated in myotubes and may be
responsible for the palm- and LPS-mac-CM-induced IR. Strikingly,
phosphorylation of p38 MAPK, JNK1 and JNK2 were all normalised
by palmitoleic-mac-CM and comb-mac-CM (Fig. 2A–C). In contrast,
all FA-palm-CMs tended to similarly activate ERK1/2 (not signifi-
cant by ANOVA; Fig. 2D), suggesting that this MAPK does not medi-
ate the differential effects of SFA and UFA treatment of
macrophages on myotube insulin sensitivity. In addition, comb-
mac-CM reduced degradation of IjBa compared to palm-mac-CM
treatment (91% increase, p = 0.049; Fig. 2E). Thus palmitoleic acid
treatment of macrophages results in CM that does not generate
an inflammatory response involving the MAPK and NFjB signalling
pathways in myotubes, in contrast to the effects of palm-mac-CM
alone. Furthermore, abrogation of the palm-mac-CM-induced
MAPK activation might underpin the insulin-sensitising effects of
palmitoleic acid.
3.4. Macrophage-conditioned medium-induced defects in glycogen
synthesis and insulin signalling are partially restored by
pharmacological MAPK inhibition
As previous findings have suggested that activation of the NFjB
pathway did not contribute to the generation of IR in muscle in vivo
(Hommelberg et al., 2011, Polkinghorne et al., 2008), next we
aimed to determine whether pharmacological inhibition of the
two MAPKs that were activated by SFA and LPS treatment of mac-
rophages could restore the impaired myotube glucose disposal.
Glycogen synthesis was measured with or without pre-incubation
with the p38 MAPK inhibitors SB203580 (1 lM) and BIRB796
(0.1 lM) (Bain et al., 2007; Kuma et al., 2005) or JNK V inhibitor
(1 lM) (Bain et al., 2007). Both palm- and LPS-mac-CM induced
increases in pY182-p38 MAPK, pT183/pY185-p46 and p54 JNK,
although in the case of LPS-mac-CM, these increases did not reach
significance by post hoc testing on this occasion, perhaps due to
variation in batches of LPS used. Nevertheless, these trends wereall abolished by the corresponding inhibitor treatment (Fig. 3A–
C), confirming the efficacy of the inhibition. Each MAPK inhibitor
alone showed similar but smaller effects when used alone (data
not shown).
The effects of MAPK and JNK inhibition on myotube glycogen
synthesis and signalling were investigated next. Inhibition of nei-
ther of these kinases had effects in non-insulin treated cells, as
would be expected based on the data presented in Fig. 2 (data
not shown). However, pre-incubation with SB203580 and BIRB796
together had dual effects on insulin-stimulated glycogen synthesis.
The 45% reduction in insulin-stimulated glycogen synthesis in
palm-mac-CM-treated cells (p = 0.0038) was nearly abolished by
inhibitor treatment, with a lesser effect in LPS-mac-CM-treated
myotubes (Fig. 4A). This was apparently contributed to by both
ameliorations of the effects of the mac-CM treatments and an
inhibitor-induced reduction in control-mac-CM insulin-stimulated
glycogen synthesis. Similarly, p38 MAPK inhibition caused a 53%
increase in insulin-stimulated pY612-IRS1 versus that in palm-
mac-CM-treated myotubes (p = 0.0183; Fig. 4B), substantially
restoring the defect. This was accompanied by partial restorations
of pS473-Akt (increased by 46%, p = 0.025), pS9-GSK3b (increased
by 51%, p = 0.0028) and pT642-AS160 (increased by 48%,
p = 0.032) (Fig. 4C-E), with p38 MAPK inhibition also limiting the
effects of insulin on phosphorylation of PI3K signalling intermedi-
ates in control cells. Interestingly, the LPS-mac-CM-induced
defects in insulin signalling were not ameliorated by p38 MAPK
inhibition (Fig. 4B-E). Indeed, there was a further 44% reduction
in pT642-AS160 compared to LPS-mac-CM treated myotubes
(p = 0.044; Fig. 4B).
JNK inhibition appeared to partially restore the palm-mac-CM-
induced defects in PI3K signalling in insulin-stimulated cells
(Fig. 4B-E), although these effects were of lower magnitude than
that induced by p38 MAPK inhibition and did not appear to be
reflected in improved glycogen synthesis (Fig. 4A). However, inhi-
bition of JNK did cause a 41% increase in pS9-GSK3b versus palm-
mac-CM (p = 0.013; Fig. 4D). Instead, JNK inhibition was more
effective in restoring the defects induced in glycogen synthesis
and phosphorylation of signalling intermediates caused by LPS-
mac-CM, in particular with regard to pS473-Akt (54% increase over
LPS-mac-CM alone; p = 0.0067; Fig. 4C), which may be the result of
a different secretory profile of macrophages induced by LPS versus
palmitic acid. Nevertheless, it appears that JNK is less important
than p38 MAPK in the palm-CM-induced defect in myotube glyco-
gen synthesis.
3.5. The palmitic acid-treated macrophage CM-induced defect in
myotube PI3K signalling is also partially restored by siRNA-induced
silencing of p38a
As pharmacological inhibition of p38 MAPK had more striking
effects than that of JNK and these effects were more obvious with
regard to insulin signalling than glycogen synthesis, we sought to
corroborate this finding by investigating the effects of siRNA-med-
iated silencing of the principal pro-inflammatory p38 MAPK iso-
form in skeletal muscle (p38a) (Kuma et al., 2005) on myotube
insulin signalling. A 74% reduction in p38a protein was obtained
(p < 0.0001; Fig. 5A) and this was sufficient to reduce collective
phosphorylation of all the p38 MAPK isoforms. Specifically, palm-
mac-CM had an additive effect with insulin (Antonescu et al.,
2005) to increase pY182-p38 MAPK, but both these increases were
abolished by siRNA. A 34% decrease in total pY182-p38 MAPK
occurred (p = 0.0007), reducing this to the level measured in con-
trol myotubes (Fig. 5B), a trend that was replicated in LPS and con-
trol-CM-incubated myotubes, again demonstrating a dual effect of
manipulating p38 MAPK on insulin signalling. Similarly, total p38
MAPK protein was reduced by a mean of 45% across all groups
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Fig. 2. Palmitic acid and palmitoleic acid-treated macrophage-conditioned media have contrasting effects on inflammatory signalling in C2C12 myotubes. C2C12 myotubes
were incubated with conditioned medium derived from macrophages treated with LPS, palmitic acid, palmitoleic acid, a combination of the two or vehicle (control group) for
16 h, before being serum starved and lysed in RIPA buffer, and SDS–PAGE and immunoblotting conducted to assess phosphorylation and total protein levels of (A) p38 MAPK
(pY182), (B) ERK1/2 (pT202), (C) p46 JNK (pT183/pY185), (D) p54 JNK (pT183/pY185) and E) IjBa. Densitometry was performed and sample blots and summary graphs are
shown, representing the mean ± SEM of 3–4 individual experiments. All treatment groups were represented on each blot on which bands were quantified, but basal and
insulin-stimulated samples are shown separately here for clarity. Total protein levels of MAPKs and b-Actin were unchanged by the treatments. Selected post hoc significance
is shown to simplify interpretation: *p < 0.05, **p < 0.01, ***p < 0.001 vs. insulin-treated control; ###p < 0.001 vs. basal control; £p < 0.05, and ££££p < 0.0001 versus palmitate
treated, insulin treated cells. C – Control (+ insulin treatment); P –Palmitic acid (+ insulin treatment); L – LPS (+ insulin treatment); PO – Palmitic and palmitoleic acid
(+ insulin treatment); O – Palmitoleic acid (+ insulin treatment).
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MAPK isoforms.
The siRNA-mediated reduction in p38 MAPKa ameliorated most
of the observed signalling defects to varying extents, as indicated
by the abolition of the significant differences in phosphorylation
between insulin-treated control and palm- or LPS-mac-CM-treatedmyotubes (Fig. 6A-D). Most clearly, there was a significant increase
in phosphorylation of Akt after palm-mac-CM treatment (58%;
p = 0.034; Fig. 6B) and a similar trend for GSK3b phosphorylation
(35% increase, p = 0.10; Fig. 6C), confirming that this was not
purely due to an inhibition of control insulin-stimulated phosphor-
ylation, although this likely contributes, as with the effects of
Fig. 3. Effects of pharmacological inhibition of MAPKs on conditioned medium-induced changes in MAPK phosphorylation. Conditioned medium from macrophages treated
with palmitic acid, LPS or vehicle (control group) was incubated with or without SB205380 (1 lM) and BIRB796 (0.1 lM), JNK V (1 lM) inhibitors or vehicle for 16 h. After
cells were serum starved for 1 h and treated with 100nM insulin for 15 min, they were collected in RIPA buffer and phosphorylation and total protein levels of (A) p38 MAPK
(pY182), (B) p46 JNK (pT183/pY185) and (C) p54 JNK (pT183/pY185) were assessed by SDS–PAGE and immunoblotting. Summary graphs show the mean ± SEM of 4
individual experiments, accompanied by representative blots. Total protein levels of signalling intermediates and b-Actin were unchanged by the treatments. Post hoc:
*p < 0.05, **p < 0.01 and ***p < 0.001 vs. no inhibitor control; £££p < 0.001 vs. no inhibitor palmitic acid; $p < 0.05 and $$p < 0.01 vs. no inhibitor LPS. C – control conditioned
medium (+ insulin treatment); P – palmitic acid-treated macrophage-conditioned medium (+ insulin treatment); L – LPS-treated macrophage-conditioned medium (+ insulin
treatment); p38 – SB205380 and BIRB796 inhibitors used; JNK – JNK V inhibitor used.
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explanation for the changes observed in AS160 phosphorylation
(Fig. 6D), or indeed this could be the result of effects upon activity
of an alternative upstream kinase, such as AMP-activated protein
kinase (AMPK) (Thong et al., 2007). However, the data are broadly
consistent with those generated using p38 MAPK inhibitors, con-
firming a role for p38 MAPK in the mechanism.3.6. Macrophages treated with palmitic acid show a pro-inflammatory
polarisation that is abrogated by co-incubation with palmitoleic acid
We next investigated the effects of each FA treatment on mac-
rophage polarisation and secretion of potential mediators of the
effects observed in the myotubes. Macrophage activation is classi-
cally defined as either M1 (pro-inflammatory) or M2 (anti-inflam-
matory), according to cellular iNOS and arginase activities (Lumeng
et al., 2007a,b), therefore NOS2 expression in, NO release by and
arginase activity of treated macrophages were measured. Macro-
phages treated with LPS demonstrated robust respective 44 and
5.6-fold increases in NOS2 and NO release over control
(p < 0.0001 and p = 0.0002; Fig. 7A and B). However, in addition,
palmitic acid-treated macrophages also showed an 18-fold
increase in NOS2 mRNA (p = 0.0074) and produced 164% more
NO than control macrophages (p = 0.012), while palmitoleic acid
and the combined treatment did not affect NOS2 mRNA or NO
release. Palmitic acid-treated macrophages also produced 44% less
urea per mg of protein than control macrophages (p = 0.034),
although the reduction caused by LPS treatment was not signifi-
cant (Fig. 7C). In contrast, palmitoleic acid or palmitic/palmitoleic
acid-treated cells produced a similar amount of urea to control
cells. Thus palmitic acid-treated macrophages demonstrate a clas-
sical pro-inflammatory M1 phenotype on the basis of these two
assays, while this shift is prevented in the presence of palmitoleic
acid.M1-activated macrophages secrete a range of pro-inflammatory
cytokines/chemokines that activate inflammatory pathways in
adjacent cells, therefore the levels of 2 pro-inflammatory cytokines
and 2 pro-inflammatory chemokines that could be implicated in
muscle IR (De Paepe et al., 2012; Hotamisligil et al., 1993; Sell
et al., 2006; Tardif et al., 2011) were measured in mac-CM. LPS
treatment of macrophages caused the expected substantial
increases in production of TNFa, MCP1 and CXCL2 (all p < 0.0001;
Fig. 7D-H). However, there were also respective 308 and 296%
increases in TNFa macrophage mRNA and peptide in palm-mac-
CM versus control (p = 0.0101 and p = 0.001; Fig. 7D and E),
changes that were normalised by concurrent palmitoleic acid incu-
bation. MCP1 mRNA was increased by 213% in macrophages
(p = 0.0074; Fig. 7F) but the increase in peptide concentration in
palm-mac-CM did not reach significance (79% increase, p = 0.15;
Fig. 7G), and this was not substantially affected by addition of pal-
mitoleic acid. No effects on CXCL2 secretion were noted (Fig. 7H),
while IL1b levels were below the level of detection for treatment
groups other than LPS-mac-CM (data not shown). This suggests
that neither CXCL2 nor IL1b are likely to be responsible for the
effects of CM in myotubes, while the evidence for a role of MCP1
is equivocal.
3.7. Addition of a TNFa blocking antibody leads to partial restoration
of the palmitic acid-treated macrophage CM-induced defect in
myotube insulin signalling
As palm-mac-CM contained elevated levels of TNFa and this
increase was prevented by co-incubation with palmitoleic acid,
we aimed to establish whether TNFa might be responsible for
the induction of myotube IR by palm-mac-CM. Preliminary exper-
iments confirmed that 2.5–100 ng/ml recombinant TNFa
decreased pS473-Akt in myotubes, confirming that TNFa is capable
of having this effect, while the TNFa blocking antibody did not
affect Akt phosphorylation. In addition, 1 ng/ml recombinant TNFa
Fig. 4. Macrophage-conditioned medium-induced defects in glycogen synthesis and insulin signalling are partially restored by pharmacological MAPK inhibition. C2C12
myotubes were incubated with conditioned medium from macrophages treated with palmitic acid, LPS or control with or without SB205380 (1 lM) and BIRB796 (both
0.1 lM; ‘‘SB + BIRB’’), JNK V (1 lM) inhibitors or vehicle (‘‘No inhibitor’’ group) for 16 h, before being serum starved and (A) incubated with D-[U-14C]-glucose tracer ± 100nM
insulin to measure glycogen synthesis, or collected in RIPA buffer and SDS–PAGE and immunoblotting conducted to assess phosphorylation and total protein levels of (B) IRS-
1 (pY612), (C) Akt (pS473), (D) GSK3b (pS9) and (E) AS160 (pT642). Densitometry was performed and these data are shown graphically alongside representative blots. Total
protein levels of signalling intermediates and b-Actin were unchanged by the treatments. Data are mean ± SEM of 4–6 individual experiments. Selected post hoc significance is
shown to simplify interpretation: *p < 0.05, **p < 0.01 ***p < 0.001 and ****p < 0.0001 vs. no inhibitor insulin-stimulated control; £p < 0.05, ££p < 0.01 vs. no inhibitor palmitic
acid; &p < 0.05 and &&p < 0.01 vs. no inhibitor LPS; ##p < 0.01 and ####p < 0.0001 vs. basal (no insulin) control. C – control conditioned medium (+insulin); P – palmitic acid-
treated macrophage-conditioned medium (+ insulin): L – LPS-treated macrophage-conditioned medium (+ insulin). BA – basal (no insulin); p38 – SB205380 and BIRB796
inhibitors used; JNK – JNK V inhibitor used.
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10 lg/ml blocking antibody, while there was no activation of this
kinase by the blocking antibody alone (data not shown). Therefore,in further experiments 10 lg/ml blocking antibody was added to
palm-mac-CM and LPS-mac-CM prior to their addition to myotube
cultures.
Fig. 5. Effects of siRNA-mediated p38 MAPKa silencing on conditioned medium-induced changes in p38 MAPK phosphorylation and protein levels in C2C12 myotubes.
Western blots were generated using lysates derived from myotubes incubated with a siRNA pool targeting p38 MAPKa or a nonsense (scrambled) control for 72 h. (A)
Silencing of p38aMAPK protein in 100nM insulin-treated C2C12 myotubes (mean 74% reduction). (B) C2C12 myotubes were incubated with conditioned medium generated
by macrophages treated with palmitic acid, LPS or vehicle (control group) ± p38a siRNA pool for 16 h. Cells were serum starved for 1 h and then treated ± 100nM insulin for
15 min. Total phosphorylation and total protein levels of p38 MAPK (all isoforms) were assessed. Summary graphs show the mean ± SEM of 4 individual experiments,
accompanied by representative blots. Selected post hoc significance is shown to simplify interpretation: ##p < 0.01 vs. scrambled siRNA, basal ***p < 0.001 and ****p < 0.0001 vs.
scrambled siRNA, insulin-treated; £££p < 0.001 vs. scrambled siRNA palmitic acid; $$p < 0.01 vs. scrambled siRNA LPS. C – control conditioned medium (+ insulin treatment);
P – palmitic acid-treated macrophage-conditioned medium (+ insulin treatment); L – LPS-treated macrophage-conditioned medium (+ insulin treatment). BA – basal
(no insulin); p38a – p38 MAPKa siRNA-treated; D3 – transfection reagent-treated only.
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signalling intermediates in control-mac-CM myotubes (all
p < 0.0001), while the addition of blocking antibody had no signif-
icant effect, although there did tend to be small reductions in each
(Fig. 8A–D). The expected reductions in phosphorylation of signal-
ling intermediates caused by palm-mac-CM and LPS-mac-CM
(p = 0.012 to p < 0.0001; Fig. 8A-D) were attenuated in the presence
of blocking antibody. There were 30–62% increases in pY612-IRS-1,
pS473-Akt, pS9-GSK3b and pT642-AS160 (range p = 0.0079 to
p = 0.0271; Fig. 8A-D) in myotubes incubated with palm-mac-CM,
which were sufficient to restore phosphorylation of each interme-
diate to near normal levels. In addition, blocking antibody lead to a
30% increase in pY612-IRS1 (p = 0.019; Fig. 8A) and a 29% increase
in pS9-GSK3b (p = 0.042; Fig. 8C) when added to LPS-mac-CM,
while Akt and AS160 phosphorylation did not change significantly.
Thus TNFa is a major mediator of the induction of myotube IR by
palm-mac-CM, while LPS-mac-CM likely has effects mediated
through other cytokines in addition to TNFa.
4. Discussion
In this study, we have utilised a model involving macrophage
treatment with an SFA, a UFA or a combination of these and appli-
cation of the CM generated to differentiated C2C12 myotubes in
culture to determine whether and how increased local infiltration
of macrophages into skeletal muscle during obesity ((Fink et al.,
2013; Hevener et al., 2007; Nguyen et al., 2007); NAT, CWJ and
MEC, unpublished data) might impact upon local insulin sensitivity
and the differential effects of FA types in this context. The principal
findings were that palmitate treatment induces an M1-type polar-
isation of macrophages and increased secretion of TNFa, which
causes activation of inflammatory/stress signalling pathways in
myotubes and thus inhibition of insulin-stimulated glucose uptake
and incorporation into glycogen, while treatment of macrophages
with palmitoleic acid results in myotube insulin sensitisation andis capable of preventing the effects of palmitate in this model.
Importantly, we verified that there was no detectable carry-over
of FAs into the CM after cell washing and that there was no effect
of control-mac-CM on myotube glycogen synthesis versus medium
that had not been incubated with macrophages (data not shown).
Our data are generally consistent with a recent study in which
CM generated by palmitate treatment of RAWmacrophages caused
reductions in glucose uptake and insulin-stimulated signalling in
GLUT4-overexpressing L6 myoblasts (Samokhvalov et al., 2008).
However, arguably our model utilising unmodified differentiated
myotubes and macrophages from the same species (mouse)
reflects the in vivo situation more closely. Interestingly, this previ-
ous study found that LPS-mac-CM actually had positive effects on
insulin signalling, while we found its effects to be similar to those
of palm-mac-CM, perhaps due to these differences in the models
used or contrasting secretory profiles of the macrophage lines.
Instead, our data are consistent with the proposal that both LPS
and SFAs activate macrophages through binding to Toll-like Recep-
tor-4 (Hwang, 2001; Lee et al., 2001; Nguyen et al., 2007). Our find-
ings also clearly implicate a role for TNFa-induced activation of
p38 MAPK, a mechanism that has been shown to impair insulin
sensitivity in muscle cells before (de Alvaro et al., 2004). The effect
of TNFa on myotubes involved activation of IKK and thus NFjB
downstream of p38 MAPK in that study, which is consistent with
the reduced levels of IjBa we observed. The Klip group have iden-
tified a role for novel PKC isoform activation in causing mac-CM-
induced effects in myoblasts (Kewalramani et al., 2011). Since pre-
viously the effects of hyperglycaemia in monocytes have been
ascribed to conventional PKC-mediated p38 MAPK activation
(Devaraj et al., 2005), it is possible that novel PKC activation may
occur upstream of p38 MAPK and IKK activation in our model.
Numerous publications have suggested that stress kinases such
as JNK, p38 MAPK and IKK serine phosphorylate IRS1, leading to
reduced tyrosine phosphorylation and thus reduced downstream
signalling to glucose disposal (Aguirre et al., 2002; Fujishiro
Fig. 6. The palmitic acid-treated macrophage-CM-induced defect in myotube PI3K signalling is partially restored by siRNA-induced silencing of p38a. Conditioned medium
from macrophages treated with palmitic acid, LPS or vehicle (control group) was used to incubate C2C12 myotubes ± a p38 MAPKa siRNA pool for 16 h. Cells were serum
starved for 1 h and treated ± 100nM insulin for 15 min. Phosphorylation and protein levels of (A) IRS-1 (pY612), (B) Akt (pS473), (C) GSK3b (pS9) and (D) AS160 (pT642) were
assessed by western blotting of lysates. Densitometry was performed on blots and summarised as graphs showing the mean ± SEM of 4 individual experiments, alongside
representative blots. Total protein levels were unchanged by any treatment. Selected post hoc significance is shown to simplify interpretation: *p < 0.05 and **p < 0.01 vs.
scrambled siRNA insulin-treated control; £p < 0.05 vs. scrambled siRNA palmitic acid; #p < 0.05, ###p < 0.001 and ####p < 0.0001 vs. basal (no insulin) sample from the same
siRNA treatment group. C – control conditioned medium (+ insulin); P – palmitic acid-treated macrophage-conditioned medium (+ insulin); L – LPS-treated macrophage-
conditioned medium (+ insulin). BA – basal (no insulin); p38a – p38 MAPKa siRNA-treated.
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2001), although IRS1-independent mechanisms have also been
proposed (Cleasby et al., 2007; Hoehn et al., 2008). We found that
activating phosphorylation of both JNK and p38 MAPK were
increased in myotubes, whereas this trend did not reach signifi-
cance in the case of ERK, as was found in a human cell co-culture
model (Varma et al., 2009). Pharmacological inhibition of p38
MAPK lead to partial restoration of palm-mac-CM-induced defects
in glucose utilisation and signalling, data that were mostly recapit-
ulated using p38 MAPKa siRNA. However, the abolition of the
palm-mac-CM effects was due at least in part to the dual effects
of p38 MAPK inhibition on insulin signalling: not only can p38
MAPK impair glucose utilisation (de Alvaro et al., 2004), but there
is some evidence that it is also required for full insulin stimulated
glucose uptake and PI3K signalling (Antonescu et al., 2005). The
lesser effects of the siRNA-mediated gene silencing may be
ascribed to the <80% reduction in p38a MAPK produced and/or
the targeting of only the a-isoform, although this is the principal
pro-inflammatory isoform in muscle (Boppart et al., 2000). Thus,
targeting of p38 MAPK in muscle may be of therapeutic benefit
for obesity-associated IR. In support of this, pharmacological inhi-bition of p38 MAPK improved basal glucose disposal in cultured
adipocytes (Carlson and Rondinone, 2005), reduced obesity and
whole body IR induced by high fat diet-feeding in rodents
(Maekawa et al., 2010) and alleviated oxidative stress-associated
IR in soleus muscle (Diamond-Stanic et al., 2011). In contrast, the
pharmacological attenuation of JNK activity did not significantly
prevent the palm-mac-CM-induced defects. Instead, this treatment
showed some efficacy in ameliorating the similar defects induced
by LPS-mac-CM, suggesting that LPS and palmitate treatment of
macrophages may result in the release of a different range of solu-
ble mediators that induce muscle IR through activation of alterna-
tive MAPKs. Indeed, Samokhvalov et al. showed that LPS treatment
of macrophages elicited secretion of the anti-inflammatory cyto-
kine IL-10, which might account for the similar effects of LPS-
mac-CM and palm-mac-CM on myotubes, despite the far larger
macrophage TNFa secretion induced by the former treatment.
Of the four cytokines/chemokines measured here, only TNFa
secretion was significantly increased by palmitic acid treatment,
but the importance of this finding was confirmed by repeating
myotube incubation with palm-mac-CM in the presence of a
TNF-a blocking antibody. This cytokine also played a role in
Fig. 7. Macrophages treated with palmitic acid show a pro-inflammatory polarisation that is abrogated by the addition of palmitoleic acid. J774 Macrophages were incubated
with 0.75 mM palmitic acid, 0.75 mM palmitoleic acid, a combination of both, LPS, or vehicle (control group) for 8 h, washed with PBS and then conditioned medium (CM)
generated for 16 h. After this period, CM and macrophages were collected and (A) macrophage mRNA expression of NOS2 was measured, (B) content of nitric oxide (lM) in
culture medium was measured using the Griess assay, (C) arginase activity was assessed based on the amount of urea (lg) produced per mg of protein, (D) TNFamRNA and
(E) TNFa peptide were measured in macrophages/CM respectively by real-time PCR/ELISA, (F) MCP1 mRNA and G) MCP1 peptide were measured in macrophages/CM
respectively and (H) CXCL2 peptide was measured in CM by ELISA. Values are the mean ± SEM of 5–6 individual experiments. Post hoc: *p < 0.05, ***p < 0.001 and ****p < 0.0001
vs. control.
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(Samokhvalov et al., 2008), while TNFa is generally well-
established as a mediator of IR, as infusion leads to reduced whole
body insulin-mediated glucose uptake in humans (Plomgaard
et al., 2005), while knockout of TNFa or its receptors protect mice
from obesity (Hotamisligil et al., 1994; Uysal et al., 1997). In sup-
port of our proposed cellular mechanism, TNFa has been shown
to induce p38 MAPK-dependent serine phosphorylation of both
the insulin receptor and IRS1, reducing insulin-stimulated PI3K
signalling, glucose uptake and GLUT4 translocation in myotubes(de Alvaro et al., 2004). However, an additional role for MCP1
(Sell et al., 2006) or other cytokines/chemokines in the mechanism
has not been ruled out.
We have shown that macrophages treated with palmitoleic acid
alone generated CM that was insulin sensitising, as well as increas-
ing basal glycogen synthesis, while addition of palmitoleic acid to a
palmitic acid incubation is also capable of preventing the IR associ-
ated with the palm-mac-CM-induced activation of MAPKs, suggest-
ing an additionalmechanismwherebyUFAs have insulin sensitising
effects in skeletal muscle. These effects may be mediated either by
βFig. 8. Addition of a TNFa blocking antibody leads to partial restoration of the palmitic acid-treated macrophage CM-induced defect in myotube insulin signalling. C2C12
myotubes were incubated with conditioned medium derived frommacrophages treated with palmitic acid, LPS or vehicle (No blocking group), with or without TNFa blocking
antibody (10 lg/ml) for 16 h, before being serum starved and lysed in RIPA buffer, and SDS–PAGE and immunoblotting conducted to assess phosphorylation and total protein
levels of (A) IRS1 (pY612), (B) Akt (pS473), (C) GSK3b (pS9) and (D) AS160 (pT642). Representative blots and summary data (mean ± SEM of 6 individual experiments) are
shown. Protein expression levels of all intermediates were unchanged by any treatment. Selected post hoc significance is shown to simplify interpretation: *p < 0.05, **p < 0.01,
***p < 0.001 ****p < 0.0001 vs. insulin-treated control; £p < 0.05; ££p < 0.01 vs. No Blocking palmitic acid; $p < 0.05 vs No Blocking LPS; ####p < 0.0001 vs. Basal control. B – Basal
(no insulin) C – Control, insulin-treated P – Palmitic acid, insulin treated, L – LPS, insulin treated. BA – Basal, B – Blocking antibody present.
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insulin sensitising effects in myotubes or by modifying activation
of intracellular signalling pathways in macrophages, although fur-
therworkwill be needed to assess these possibilities. Similar effects
of palmitate andpalmitoleate onbonemarrow-derivedmacrophage
M1/M2 polarisation have been observed previously (Prieur et al.,
2011), while UFAs have been shown to prevent SFA-induced NFjB
activation (Lee et al., 2001) in macrophages.
Palmitate and palmitoleate have distinct direct effects upon
insulin-stimulated glucose disposal in L6 myotubes (Dimopoulos
et al., 2006), but the effects of palmitoleate were not shown to
be mediated through a protective effect on insulin signalling previ-
ously. However, others have shown that oleate protects against the
effects of palmitate by reducing the impairment in PI3K signalling
(Coll et al., 2008; Gao et al., 2009) and through anti-inflammatory
effects (Coll et al., 2008), including prevention of MAPK activation
(Kadotani et al., 2009). This is likely mediated through reduced
synthesis of ceramide and/or diacylglycerol in palmitate-treated
myotubes (Chavez and Summers, 2003), rather than accumulation
of the more inert triacylglycerol and this mechanism may also
result in increased pro-inflammatory cytokine production by mac-
rophages (Schilling et al., 2013).
Our data imply that palmitoleate has dual effects in muscle
when mediated through the altered secretory milieu generated by
macrophage treatment, on both basal and insulin-stimulatedglucose disposal, associated with activation of the PI3K signalling
pathway. Importantly, the beneficial effects of palmitoleic acid have
also been demonstrated in vivo, as IR is improved by the feeding of a
diet high in UFAs (Tardif et al., 2011) and by infusion of palmitoleate
(Cao et al., 2008) in rodents. Indeed, Cao et al. proposed that palm-
itoleate represented a specific novel lipid signal, or ‘‘lipokine’’,
which is not found in large amounts in the diet, but instead is
released in more substantial amounts from adipose tissue and reg-
ulates muscle metabolism (Cao et al., 2008; Pinnick et al., 2012).
5. Conclusions
We have demonstrated that IR in muscle may at least in part
result from the effects of SFAs on local macrophages, causing
release of pro-inflammatory cytokines, paracrine activation of
stress signalling in adjacent muscle fibres and thus impaired insu-
lin-stimulated glucose incorporation into glycogen. This phenome-
non is likely to be of most significance when increased numbers of
macrophages accumulate in muscle during obesity. Further work
must aim to establish whether this represents a quantitatively
important mechanism of generation of muscle IR in vivo. The pres-
ence of palmitoleate is sufficient to prevent these effects, although
it is unclear whether this reflects a universal property of UFAs or a
‘‘lipokine’’ effect. Nevertheless, these findings serve to reinforce the
likely health benefits of a diet rich in UFAs rather than SFAs and
N.A. Talbot et al. /Molecular and Cellular Endocrinology 393 (2014) 129–142 141suggest that therapeutic targeting of TNFa action and p38 MAPK
activity remain potential approaches for the treatment of T2D.
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